Chemotherapy for Oligodendroglioma
- 1 February 1991
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 48 (2) , 225-227
- https://doi.org/10.1001/archneur.1991.00530140123026
Abstract
Six years ago, we began to notice that recurrent oligodendrogliomas, tumors that had regrown after one or more surgeries and radiotherapy, responded to chemotherapy. These tumors were clinically aggressive, contrast-enhancing, histologically anaplastic, and relatively pure. We concluded, after eight consecutive responses (see reference 1 for response criteria),1that anaplastic oligodendroglioma was a chemosensitive tumor.2In this article, we review our experience with chemotherapy for this uncommon brain tumor. Table 1 summarizes the results of treatment for "first" recurrence. We have treated 10 patients, all have responded; two completely and eight partially. Patient 1 responded to carmustine (BCNU), patient 4 to diaziquone (AZQ), the others to a drug combination (PCV) that included procarbazine, lomustine (CCNU), and vincristine.3(Patient 5 failed to respond to fludarabine, patient 8 to diaziquone; both responded to PCV.) The median duration of response is 15 months (range, 8 to 36 months). All patients haveKeywords
This publication has 2 references indexed in Scilit:
- Successful chemotherapy for newly diagnosed aggressive oligodendrogliomaAnnals of Neurology, 1990
- Successful chemotherapy for recurrent malignant oligodendrogliomaAnnals of Neurology, 1988